Portfolio weekly update Took the opportunity in the beginning of the week when $Sanion was down almost 10% and almost doubled the position. Good call and Saniona up around 12% on the week. $Dawn also had a fine week with around +15%. Portfolio all in all up around 6%.

Nice to see $Dawn come out with strength on an otherwise tough week. Hearing of buyout rumors, time will tell. $Sanion getting traction, dont know the reason otherwise that the fall yesterday was way to big and some changes at the Cofepris lists. Not saying we have a decision.

Pretty calm week, steady and about +6% on the week. Biggest movers $Sanion (+8,5%) and $Dawn (+10%). Will be an exciting next week and expecting big moves ahead. Think we will have more(final?) regarding Mexico/teso and some data from $Elic.

Cash stood at $441.1 million end-2025. Priorities include global expansion, Phase 3 FIREFLY-2 enrollment completion by H1 2026, and initial Emi-Le clinical data mid-2026. Presentation at J.P. Morgan Conference today. Excited and confident this will be a great year.

The company, post-Mersana acquisition, highlights pipeline advancements including Emi-Le and DAY301. CEO Jeremy Bender emphasized commercial momentum in relapsed pLGG and future data from frontline trials. >>>

$Dawn today announced preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year-over-year, with Q4 at $52.8 million (37% QoQ growth) driven by rising patient demand. For 2026, U.S. OJEMDA revenue is projected at $225-$250 million, a 53% midpoint increase. >>>

Interesting next week. $Klto will be at BiotechShowcase2026 in San Francisco and $Crno, $Dawn and $Sanion will all be at JPM week. Presenting and hopefully productful meetings will be held. We don't want to go all over the Atlantic and come home emtpy handed...(Cereno/Saniona)

A little portfolio update after this first week. Nothing nuclear but notable that $klto gained 17%, and $Elic 16% since i bought them earlier this week. ▪︎ $Dawn finished the Mersana acquisition. ▪︎ Elicera positive p1/p2a data for ELC-100. >>>

This validates ELC-100's mechanism, which selectively infects and destroys cancer cells while potentially boosting immunity. CEO highlighted the results as encouraging, crediting V. NET Foundation's support. Elicera now plans strategic partnerships for further development.

..and established a maximum tolerated dose of 1x10^12 virus particles. ELC-100 was well-tolerated and showed efficacy signals: two partial responses and six progression-free cases at 12 weeks among eight evaluable patients. >>>

Elicera Therapeutics announced final data from its phase I/IIa trial of ELC-100, an oncolytic virus targeting neuroendocrine tumors (NETs). The study, involving 12 advanced metastatic NET patients, met its primary safety goal with no dose-limiting toxicities... >>>

Initial data indicate good tolerability and objective responses across tumor types, addressing high unmet needs in adult and pediatric oncology. The first piece of the puzzle for 2026 in place.

B7-H4 is overexpressed in ACC and other cancers. Launched in 2022, the multicenter trial assesses safety, tolerability, and efficacy in solid tumors like ACC, breast, endometrial, and ovarian cancers. >>>

This expands Day One's pipeline with Emi-Le (emiltatug ledadotin). Emi-Le is an investigational B7-H4-targeted ADC with a DAR of 6 and proprietary payload, showing early anti-tumor activity in a Phase 1 study for ACC, a rare cancer lacking treatments. >>>

$Dawn completed its acquisition of Mersana Therapeutics on January 6, 2026, for $25 per share in cash plus a non-tradable CVR potentially worth up to $30.25, totaling up to $55.25 per share. The deal, makes Mersana a wholly owned subsidiary and delists its stock from Nasdaq. >>

Epigenetics and the Klotho Clock: Aging causes Klotho gene silencing via promoter methylation. The company’s AAV therapy provides long-term protein expression. The Klotho Clock blood test measures methylation to assess biological age and balance clinical trials.

Preclinical to Clinical: Mouse/primate studies show Klotho's efficacy in ALS, Alzheim., and Parkin. models. Human trials target measurable outcomes in neurodeg. and age-related diseases (muscle wasting, kidney issues), bypassing impractical direct lifespan extension studies.

Klotho Neurosciences' Approach: Founded by CEO Dr. Joseph Sinkule, the company develops gene therapies like KLTO-202, using AAV vectors to deliver Klotho to neurons for ALS treatment. This aims to protect motor function by addressing neurodegeneration linked to aging.

Klotho's Role in Aging: Identified in mice, Klotho influences kidney, brain, muscle, and cardiovascular systems. Overexpression extends lifespan; deficiency accelerates decline. It acts as a neuroprotective, anti-inflammatory protein that clears cellular debris.

Some key takeaways from a great and interesting article about Klotho Neurosciences released in November. $Klto https://t.co/DVrBDVUAYI